村松 崇

Medicine & Life Sciences

1. Stents 100%
2. Everolimus 72%
3. Percutaneous Coronary Intervention 72%
4. Drug-Eluting Stents 60%
5. Blood Vessels 52%
6. Optical Coherence Tomography 46%
7. Coronary Artery Disease 45%
8. Coronary Vessels 36%
9. Coronary Angiography 36%
10. Thrombosis 33%
11. Myocardial Infarction 31%
12. ST Elevation Myocardial Infarction 26%
13. Mortality 25%
14. Valsartan Drug Combination Amlodipine 23%
15. Atrial Fibrillation 19%
16. Brain Natriuretic Peptide 19%
17. Atherosclerotic Plaques 19%
18. Pathologic Constriction 18%
19. Technology 18%
20. Heart Failure 17%
21. Clinical Trials 17%
22. Cardiovascular Diseases 16%
23. Cardiology 16%
24. Equipment and Supplies 16%
25. Computed Tomography Angiography 15%
26. Angiography 14%
27. Acute Coronary Syndrome 14%
28. Taxus 14%
29. Therapeutics 13%
30. fibrin fragment D 13%
31. Incidence 13%
32. Arteries 12%
33. Neointima 12%
34. Area Under Curve 11%
35. Fatty Acid-Binding Proteins 11%
36. Cardiac Resynchronization Therapy 11%
37. Polymers 10%
38. Thrombectomy 10%
39. Investigational Therapies 10%
40. Hydrodynamics 10%
41. Tunica Intima 9%
42. Left Ventricular Hypertrophy 9%
43. Glucose Intolerance 9%
44. Sirolimus 9%
45. Safety 8%
46. Coronary Stenosis 8%
47. umirolimus 8%
48. Hypertension 8%
49. Insulin Resistance 8%
50. Body Mass Index 8%